Gene-editing stocks are risky with a big upside, particularly for long-term investors. The science is revolutionizing medicine, with the potential to create cures, rather than just treatments. While, most gene-editing companies aren’t yet profitable, the sector is seen as having a double-digit CAGR over the next decade. The Institute for Clinical and Economic Review (ICER) says exa-cel alone  could be worth as much as $1.35 million to $2 million per treatment because it would end the need for long-term therapies for SCD or TDT.